Björn Ambrosius

ORCID: 0000-0003-3679-7907
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Multiple Sclerosis Research Studies
  • Peripheral Neuropathies and Disorders
  • Neuroinflammation and Neurodegeneration Mechanisms
  • HIV Research and Treatment
  • Pharmacological Effects of Natural Compounds
  • Toxin Mechanisms and Immunotoxins
  • Tryptophan and brain disorders
  • Systemic Sclerosis and Related Diseases
  • Ion Channels and Receptors
  • Pain Mechanisms and Treatments
  • Reproductive System and Pregnancy
  • Immune Response and Inflammation
  • Autoimmune Neurological Disorders and Treatments
  • Fibromyalgia and Chronic Fatigue Syndrome Research
  • Herpesvirus Infections and Treatments
  • Salivary Gland Disorders and Functions
  • Cytomegalovirus and herpesvirus research
  • Nerve injury and regeneration
  • Systemic Lupus Erythematosus Research
  • Pediatric health and respiratory diseases
  • Sphingolipid Metabolism and Signaling
  • Herbal Medicine Research Studies
  • Psychosomatic Disorders and Their Treatments
  • Rheumatoid Arthritis Research and Therapies
  • Neurogenesis and neuroplasticity mechanisms

St. Josef-Hospital
2015-2021

Ruhr University Bochum
2014-2021

Johannes Gutenberg University Mainz
2020

University Medical Center of the Johannes Gutenberg University Mainz
2020

University of Bern
2020

University Hospital of Bern
2019-2020

Philipps University of Marburg
2020

University of KwaZulu-Natal
2018

University of Lübeck
2018

University Hospital Schleswig-Holstein
2018

Patrick Ostkamp Anke Salmen Béatrice Pignolet Dennis Görlich Till F. M. Andlauer and 95 more Andreas Schulte‐Mecklenbeck Gabriel González‐Escamilla Florence Bucciarelli Isabelle Gennero Johanna Breuer Gisela Antony Tilman Schneider‐Hohendorf Nadine Mykicki Antonios Bayas Florian Then Bergh Stefan Bittner Hans‐Peter Hartung Manuel A. Friese Ralf A. Linker Felix Luessi Klaus Lehmann‐Horn Mark Mühlau Friedemann Paul Martin Stangel Björn Tackenberg Hayrettin Tumani Clemens Warnke Frank Weber Brigitte Wildemann Uwe K. Zettl Ulf Ziemann Bertram Müller‐Myhsok Tania Kümpfel Luisa Klotz Sven G. Meuth Frauke Zipp Bernhard Hemmer Reinhard Hohlfeld David Brassat Ralf Gold Catharina C. Groß Carsten Lukas Sergiu Groppa Karin Loser Heinz Wiendl Nicholas Schwab Antonios Bayas Susanne Rothacher Stephanie Starke Friedemann Paul Judith Bellmann‐Strobl Janina Behrens Jan-Markus Dörr René M. Gieß Joseph Kuchling Ludwig Rasche Ralf Gold Andrew T. Chan Gisa Ellrichmann Anna Lena Fisse Anna Gahlen Thomas Grüter Aiden Haghikia Robert Hoepner U.-V. Koc Carsten Lukas Jeremias Motte Kalliopi Pitarokoili Anke Salmen Ruth Schneider Joanna Schöllhammer Christoph Schroeder Björn Ambrosius Seray Demir Clemens Warnke Thomas Dehmel Kathleen Ingenhoven Ralf A. Linker De-Hyung Lee Alexandra Lämmer Eva Sauer Christoph Heesen Jan‐Patrick Stellmann Martin Stangel Lena Boenig Stefan Gingele Martin W. Hümmert Philipp Schwenkenbecher Thomas Skripuletz Wolfram Suehs Brigitte Wildemann Mirjam Korporal‐Kuhnke Hanna Oßwald Alexander Schwarz Andrea Viehöver Volker Limmroth Kathrin Gerbershagen Florian Then Bergh Barbara Ettrich Steffi Gray

Multiple sclerosis (MS) disease risk is associated with reduced sun-exposure. This study assessed the relationship between measures of sun exposure (vitamin D [vitD], latitude) and MS severity in setting two multicenter cohort studies (nNationMS = 946, nBIONAT 990). Additionally, effect-modification by medication photosensitivity-associated MC1R variants was assessed. High serum vitD a score (MSSS), for relapses, lower disability accumulation over time. Low latitude higher vitD, MSSS, fewer...

10.1073/pnas.2018457118 article EN cc-by-nc-nd Proceedings of the National Academy of Sciences 2020-12-29

To assess clinical characteristics, distribution of disease-modifying treatments (DMTs), and neuropsychological symptoms in a large cohort patients with early-stage MS.The German National MS Cohort is multicenter prospective longitudinal study that has recruited DMT-naive clinically isolated syndrome (CIS) relapsing-remitting (RRMS) since 2010. We evaluated their baseline characteristics the prevalence symptoms.Of 1,124 patients, 2.2:1 female-to-male ratio median age at onset 31.71 years...

10.1212/nxi.0000000000000446 article EN cc-by-nc-nd Neurology Neuroimmunology & Neuroinflammation 2018-03-02

Abstract Background Only few studies describe the impact of nutritive factors on chronic inflammatory demyelinating polyneuropathy (CIDP), an disease peripheral nervous system. The active component chili pepper, capsaicin, is direct agonist transient receptor potential channel vanilloid subfamily member 1. Its anti-inflammatory effect in animal model experimental autoimmune neuritis (EAN) has been previously demonstrated. Methods In present study, we and anti-oxidative influence capsaicin...

10.1186/s12974-020-01821-5 article EN cc-by Journal of Neuroinflammation 2020-05-06

Abstract Pain is frequent in multiple sclerosis (MS) and includes different types, with neuropathic pain (NP) being most closely related to MS pathology. However, prevalence estimates vary largely, causal relationships between biopsychosocial factors are largely unknown. Longitudinal studies might help clarify the determinants of MS. To this end, we analyzed data from 410 patients newly diagnosed clinically isolated syndrome or relapsing-remitting participating prospective multicenter German...

10.1097/j.pain.0000000000001767 article EN Pain 2020-01-29

HIV-associated neurocognitive disorders (HAND) affect about 50% of infected patients despite combined antiretroviral therapy (cART). Ongoing compartmentalized inflammation mediated by microglia which are activated HIV-infected monocytes has been postulated to contribute neurotoxicity independent from viral replication. Here, we investigated effects teriflunomide and monomethylfumarate on monocyte/microglial activation neurotoxicity. Human monocytoid cells (U937) transduced with a minimal...

10.1186/s12974-017-0829-2 article EN cc-by Journal of Neuroinflammation 2017-03-11

Cognitive impairment (CI) affects approximately one-third of the patients with early multiple sclerosis (MS) and clinically isolated syndrome (CIS). Little is known about factors predicting CI progression after initial diagnosis. Neuropsychological screening data from baseline 1-year follow-up a prospective multicenter cohort study (NationMS) involving 1123 newly diagnosed MS or CIS were analyzed. Employing linear multilevel models, we investigated whether demographic, clinical conventional...

10.1007/s00415-018-9142-y article EN cc-by Journal of Neurology 2018-12-04

Background Dimethyl fumarate is an immunomodulatory and neuroprotective drug, approved recently for the treatment of relapsing-remitting multiple sclerosis. In view limited therapeutic options human acute chronic polyneuritis, we used animal model experimental autoimmune neuritis in Lewis rat to study effects dimethyl on inflammation neuroprotection peripheral nervous system. Methods Findings Experimental was induced by immunization with neuritogenic peptide (amino acids 53–78) P2 myelin...

10.1371/journal.pone.0143416 article EN cc-by PLoS ONE 2015-11-30

Objective Progressive multiple sclerosis is characterized by chronic inflammation with microglial activation, oxidative stress, accumulation of iron and continuous neurodegeneration inadequate effectiveness medications used so far. We now investigated effects on microglia the previously identified neuroprotective antipsychotic clozapine in vitro experimental autoimmune encephalomyelitis (EAE). Methods Microglia were treated followed analysis cell death response to cytokine release neuronal...

10.3389/fimmu.2021.656941 article EN cc-by Frontiers in Immunology 2021-05-03

Autoimmune neuropathies are common PNS disorders and effective treatment is challenging. Environmental influence dietary components known to affect the course of autoimmune diseases. Capsaicin as pungent component chili-peppers in human nutrition. An capsaicin on diseases has been postulated. We tested animal model experimental neuritis (EAN) Lewis rat. Rats were immunized with P2-peptide treated different preventive settings. Electrophysiological, histological, molecular biological analyses...

10.1186/s12974-018-1165-x article EN cc-by Journal of Neuroinflammation 2018-04-24

Fingolimod, a sphingosine-1-phosphate receptor modulator with well-described immunomodulatory properties involving peripheral immune cell trafficking, was the first oral agent approved for treatment of relapsing remitting multiple sclerosis. Analogous options chronic autoimmune neuropathies are lacking. We tested fingolimod in animal model experimental neuritis Lewis rat. Six to eight-week-old female rats were immunized P2 peptide and from this day on treated fingolimod. Histology sciatic...

10.1186/s12974-017-0864-z article EN cc-by Journal of Neuroinflammation 2017-04-26

Corticosteroids dominate in the treatment of chronic autoimmune neuropathies although long-term use is characterized by devastating side effects.We introduce intrathecal application synthetic steroid triamcinolone (TRIAM) as a novel therapeutic option experimental neuritis Lewis rats RESULTS: After immunization with neuritogenic P2 peptide, we show dose-dependent effect one injection 0.3 or 0.6 mg/kg TRIAM on clinical and electrophysiological parameters lower degree inflammatory infiltrates...

10.1186/s12974-019-1445-0 article EN cc-by Journal of Neuroinflammation 2019-03-09

To assess the impact of APOE polymorphisms on cognitive performance in patients newly diagnosed with clinically isolated syndrome (CIS) or relapsing-remitting MS (RRMS).This multicenter cohort study included 552 untreated recently CIS RRMS according to 2005 revised McDonald criteria. The single nucleotide rs429358 (ε4) and rs7412 (ε2) haplotype were assessed by allelic discrimination assays. Cognitive was evaluated using 3-second paced auditory serial addition test Multiple Sclerosis...

10.1212/nxi.0000000000000728 article EN cc-by-nc-nd Neurology Neuroimmunology & Neuroinflammation 2020-05-02

Abstract Several neuroimmunological registries have been established in Germany during the last 10 years. The common aim is to investigate course of different diseases, mainly under various therapeutic conditions, identify predictive factors as well side effects immunomodulating therapies. Six nationwide will be presented this article. German Network for Research on Autoimmune Encephalitis (GENERATE) with more than 40 participating clinical centers and 570 documented patients (September...

10.1055/s-0043-108830 article EN cc-by-nc-nd Neurology International Open 2018-01-01

Zusammenfassung In den letzten 10 Jahren wurden in Deutschland mehrere neuroimmunologische Register aufgebaut. Grundlegendes Ziel ist es, mehr über Verlauf der entsprechenden Erkrankung, insbesondere unter therapeutischen Bedingungen, oder auch Nebenwirkungen eingesetzter Immuntherapeutika zu erfahren, im besten Fall prädiktive Marker identifizieren. Sechs dieser möchten wir folgenden Artikel vorstellen. Das Deutsche Netzwerk zur Erforschung autoimmuner Enzephalitiden (GENERATE) mit als 40...

10.1055/s-0043-108909 article DE Aktuelle Neurologie 2018-02-01

We used the animal model of experimental autoimmune neuritis (EAN) in Lewis rat to study effects dimethyl fumarate (DMF) on intestinal immune regulation.

10.1212/wnl.88.16_supplement.p2.357 article EN Neurology 2017-04-18

Objective To investigate whether inflammatory changes and markers of neurodegeneration occur in CSF HIV-infected patients already prior to neurocognitive symptoms. Background Prevalence especially milder forms HIV-associated disorders (HAND) is high despite profound efficacy highly active antiretroviral therapy. Reliable biomarkers defining at risk are lacking. Methods Cerebrospinal fluid HIV+ without neuropsychological impairment (n=45) controls with non-inflammatory neurological (NIND,...

10.1212/wnl.82.10_supplement.p7.039 article EN Neurology 2014-04-08

OBJECTIVE:We investigated the neuroprotective effect of laquinimod (LQ) in experimental autoimmune neuritis (EAN), a rat model acute peripheral polyneuritis (Guillain-Barre Syndrome). BACKGROUND:LQ is an orally administered, active immunomodulator with potential phase 3 studies for patients multiple sclerosis. It induces overexpression brain-derived neurotrophic factor (BDNF) cortex mice encephalomyelitis (EAE), sclerosis. DESIGN/METHODS:Active EAN was induced by immunization peptide aa...

10.1212/wnl.84.14_supplement.p4.107 article EN Neurology 2015-04-06
Coming Soon ...